eXoZymes, Inc.

NASDAQ:EXOZ

Biotechnology

Healthcare
$5.54 +16.75%

+$1.06 today

Market cap
$51.42M
Beta
2.66
P/E (TTM)
-6.5
EPS (TTM)
-$1.14
52W Low $6.33High $18.40

Volume 0.01M

Average 0.01M

EXOZ Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

eXoZymes, Inc.NASDAQ: EXOZ

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development grows in line with its trailing trend

Q1 FY2026 research & development of $1.12M rose 95.0% year over year, behind the +96.3% change in trailing-twelve-month research & development. Sequentially, it rose 0.8% from the prior quarter. Over 3 fiscal years it compounded at +120.0% a year.

Context

  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +95.0% toward the trailing-twelve-month pace of +96.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.12M+0.8% QoQ
Last fiscal yearDec 2025
$3.71M+98.4% YoY
LTMMar 2026
$4.25M+96.3% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+95.0%——
1 year+98.4%——
3-year CAGR+120.0%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
3.71M USD
Year-over-year change
+98.4%
4-year CAGR
+69.0%

Research & Development vs competitors

How EXOZ compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +96.3% is the 3rd highest of 7, against a peer median of +33.3%.
  • Over three fiscal years its annual growth of +120.0% compares with a peer median of -0.2%.
EXOZ Competitors
Research & Development for EXOZ and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CGTXCognition Therapeutics, Inc.LTM Mar 2026$32.45M USD-22.6%+7.0%—
SRZNSurrozen, Inc.LTM Mar 2026$32.14M USD+45.7%-7.4%428.8%
TILInstil Bio, Inc.LTM Mar 2026$20.04M USD+101.3%-58.6%—
ONCYOncolytics Biotech Inc.LTM Mar 2026CA$19.63M CAD+4.7%+15.5%—
GLSIGreenwich LifeSciences, Inc.LTM Mar 2026$15.76M USD+21.0%+38.5%—
TLSATiziana Life Sciences LtdFY2025$10.28M USD+96.6%-13.6%—
EXOZeXoZymes, Inc.LTM Mar 2026$4.25M USD+96.3%+120.0%—
Peer median (excluding EXOZ) —+33.3%-0.2%428.8%

Competitors are the stored peer set for EXOZ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue59.41K147.75K0267.38K0
Gross Profit(59.41K)(147.75K)0(267.38K)0
Gross Margin—————
Research & Development454.45K348.08K527.48K1.87M3.71M
Selling, General & Admin778.99K836.83K1.34M3.8M5.91M
Operating Expenses1.23M1.18M1.8M5.66M9.72M
Depreciation & Amortization59.41K147.75K196.94K267.38K287.96K
EBITDA(1.15M)(1.18M)(1.8M)(5.59M)(8.98M)
EBITDA Margin—————
Operating Income(1.29M)(1.33M)(1.8M)(5.93M)(9.72M)
Operating Margin—————
Interest Income09810077.61K0
Interest Expense00000
Other Income / Expenses83.74K98(199.9K)70.77K452.53K
Income Before Tax(1.21M)(1.33M)(2M)(5.86M)(9.26M)
Pre-Tax Margin—————
Income Tax Expense063.56K42.27K0(105.21K)
Net Income(1.21M)(1.4M)(2.04M)(5.86M)(9.16M)
Net Margin—————
EPS (Basic)(0.15)(0.17)(0.25)(0.72)(1.09)
EPS (Diluted)(0.15)(0.17)(0.25)(0.72)(1.09)
Weighted Avg Shares8.13M8.13M8.13M8.13M8.38M
Weighted Avg Shares (Diluted)8.13M8.13M8.13M8.13M8.38M

eXoZymes, Inc.

NASDAQ:EXOZ

Intrinsic Alpha fair value

Locked

Current Price

$5.54

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.